TNF-α induced epithelial mesenchymal transition increases stemness properties in renal cell carcinoma cells

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 12, 2014, Pages 4951-4958

  Zhang, Linlin ^a   Jiao, Min ^a   Wu, Kaijie ^a   Li, Lei ^a   Zhu, Guodong ^a   Wang, Xinyang ^a   He, Dalin ^a   Wu, Dapeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cancer stem cell; Epithelial mesenchymal transition; Renal cell carcinoma; Stemness; TNF

Indexed keywords

BMI1 PROTEIN; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR ZEB1; TUMOR NECROSIS FACTOR ALPHA; UVOMORULIN; VIMENTIN;

ARTICLE; CANCER STEM CELL; CELL STRUCTURE; CELLULAR PARAMETERS; CLONOGENIC ASSAY; COLONY FORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GROWTH CURVE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MICROSCOPY; PHENOTYPE; PROTEIN EXPRESSION; RENAL CELL CARCINOMA CELL LINE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STEMNESS; TUMOR RECURRENCE; TUMORSPHERE FORMATION; UPREGULATION; WESTERN BLOTTING;

EID: 84921459327     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414: 105-111.
2. Pietras A. Cancer stem cells in tumor heterogeneity. Adv Cancer Res 2011; 112: 255-281.
3. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med 2014; 3: 17.
4. Wu Y, Zhou BP. New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 2008; 40: 643-650.
5. Gil J, Stembalska A, Pesz KA, Sasiadek MM. Cancer stem cells: the theory and perspectives in cancer therapy. J Appl Genet 2008; 49: 193-199.
6. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
7. Zhang L, Li L, Jiao M, Wu D, Wu K, Li X, Zhu G, Yang L, Wang X, Hsieh JT, He D. Genistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathway. Cancer Lett 2012; 323: 48-57.
8. Zhang L, Jiao M, Li L, Wu D, Wu K, Li X, Zhu G, Dang Q, Wang X, Hsieh JT, He D. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J Cancer Res Clin Oncol 2012; 138: 675-686.
9. Guan Y, Gerhard B, Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 2003; 101: 3142-3149.
10. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50.
11. Hemmings C. The elaboration of a critical framework for understanding cancer: the cancer stem cell hypothesis. Pathology 2010; 42: 105-112.
12. Besançon R, Valsesia-Wittmann S, Puisieux A, Caron de Fromentel C, Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 2009; 16: 394-416.
13. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA. Epithelialmesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009; 119: 1438-1449
14. Yasui K, Shimamura M, Mitsutake N, Nagayama Y. SNAIL induces epithelial-to-mesenchymal transition and cancer stem cell-like properties in aldehyde dehydroghenase-negative thyroid cancer cells. Thyroid 2013; 23: 989-996.
15. Devarajan E, Song YH, Krishnappa S, Alt E. Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells. Int J Cancer 2012; 131: 1023-1031.
16. Yi SY, Hao YB, Nan KJ, Fan TL. Cancer stem cells niche: a target for novel cancer therapeutics. Cancer Treat Rev 2013; 39: 290-296.